1
|
Pinto Tasende JA, Fernandez-Moreno M, Vazquez-Mosquera ME, Fernandez-Lopez JC, Oreiro-Villar N, De Toro Santos FJ, Blanco-García FJ. Increased synovial immunohistochemistry reactivity of TGF-β1 in erosive peripheral psoriatic arthritis. BMC Musculoskelet Disord 2023; 24:246. [PMID: 36997896 PMCID: PMC10061727 DOI: 10.1186/s12891-023-06339-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 03/20/2023] [Indexed: 04/01/2023] Open
Abstract
BACKGROUND Immune and non-immune cells contribute to the pathology of chronic arthritis, and they can contribute to tissue remodeling and repair as well as disease pathogenesis. The present research aimed to analyze inflammation and bone destruction/regeneration biomarkers in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), osteoarthritis (OA), and ankylosing spondylitis (AS). METHODS Samples were obtained from the inflamed knee of patients with knee arthritis who had been referred for undergoing arthroscopies. The synovial membrane was processed for pathological description, IHC analysis, and quantification of mRNA expression ratio by qRT-PCR. Serum levels of TGF-β1, IL-23, IL-6, IL-17 A, IL-22, Dkk1, Sclerostin, BMP2, BMP4, Wnt1, and Wnt5a were measured by ELISA. All these data were analyzed and compared with the demographic, clinical, blood tests, and radiological characteristics of the patients. RESULTS The synovial membrane samples were obtained from 42 patients for IHC, extraction, and purification of RNA for synovial mRNA expression analysis, and serum for measuring protein levels from 38 patients. IHC reactivity for TGF-β1 in the synovial tissue was higher in patients with psoriatic arthritis (p 0.036) and was positively correlated with IL-17 A (r = 0.389, p = 0.012), and Dkk1 (r = 0.388, p = 0.012). Gene expression of the IL-17 A was higher in PsA patients (p = 0.018) and was positively correlated with Dkk1 (r = 0.424, p = 0.022) and negatively correlated with BMP2 (r = -0.396, p = 0.033) and BMP4 (r = -0.472, p = 0.010). It was observed that IHC reactivity for TGF-β1 was higher in patients with erosive PsA (p = 0.024). CONCLUSIONS The IHC reactivity of TGF-β1 in synovial tissue was higher in patients with erosive psoriatic arthritis, and TGF-β1 was in relation to higher levels of gene expression of IL-17 A and Dkk1.
Collapse
Affiliation(s)
- Jose A Pinto Tasende
- Department of Rheumatology-INIBIC, Complexo Hospitalario Universitario de A Coruña, 84 Xubias de Arriba Road, 15006, A Coruña, Spain.
| | - M Fernandez-Moreno
- INIBIC, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | | | - J C Fernandez-Lopez
- Department of Rheumatology-INIBIC, Complexo Hospitalario Universitario de A Coruña, 84 Xubias de Arriba Road, 15006, A Coruña, Spain
| | - N Oreiro-Villar
- Department of Rheumatology-INIBIC, Complexo Hospitalario Universitario de A Coruña, 84 Xubias de Arriba Road, 15006, A Coruña, Spain
| | - F J De Toro Santos
- Department of Rheumatology, Complexo Hospitalario Universitario de A Coruña, Universidade de A Coruña, A Coruña, Spain
| | - F J Blanco-García
- Department of Rheumatology-INIBIC, Complexo Hospitalario Universitario de A Coruña, Universidade de A Coruña, A Coruña, Spain
| |
Collapse
|
2
|
Ruvalcaba-Limon E, Rodriguez-Cuevas S, Hidalgo-Miranda A, Villa-Romero A, Bautista-Piña V, Rebollar-Vega R, Fernandez-Lopez JC, Morales-Vasquez F. Abstract P6-09-18: Predictive factors of pathologic complete response to neoadjuvant chemotherapy in patients with Luminal HER2(-) local advanced breast cancer using the DMET microarray. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Patients with similar local advanced breast cancer (LABC) could respond different to neoadjuvant chemotherapy (NC). Luminal HER2(-) tumors have pathologic complete response (pCR) by 5-7%. Ki67, tumor grade and hormonal receptors, could be helpful but not enough to choice between NC vs. initial surgery. Response to drugs depends on enzymes involved in absorption, distribution, metabolism and elimination (ADME); the drug-metabolizing enzyme and transporter platform (DMET), could identify 1936 single nucleotide polymorphism (SNP) from 225 genes involved in ADME proccess.
Objective
To identify predictive factors to pCR in patients with Luminal HER2(-) LABC underwent NC, to distinguish wish patients could have a real benefit from NC.
Material and Methods
This is a prospective nested case control study (1:4) with LABC patients, pure invasive ductal carcinoma Luminal HER2(-) subtypes, and sequential NC (anthracyclines and taxanes). Cases were defined as patients with pCR (Residual Cancer Burden=0), and controls those without pCR. SNPs were evaluated from DNA of leucocytes using DMET microarrays by Affymetrix.
Bivariate analyses were used as appropriate. Microarrays were processed by the DMET analyzer console. OR and 95%CI were used to test association between pCR and variables with a non-conditional logistic regression analysis; p value ≤0.05 was considered statistically significant (two-sided).
Results
From 2005 to 2014, of 3762 treated patients, 287 women met inclusion criteria. We included 117 patients, 21 cases and 96 controls. Patients with pCR were 5 years younger than controls (45.4 vs 49.4), have more grade-3 tumors, (66.7 vs 22.3%), more Luminal B subtypes (90.5 vs 64.6%), lower expression of estrogen receptor (60 vs 80%) and higher Ki67 expression (65 vs 12%), all with p≤0.05. No differences in toxicity existed between groups.
In an initial screening procedure, 13 SNPs were identified, but only 4 SNPs (4 genes) are known to participate in ADME of antineoplastic agents. All pCR cases did not have the C/C allelic variant in the rs2072671 SNP (CDA gene); while in rs1883322 SNP (PPARD gene) all had T/T variant
SNPs identified in DMET microarray known to participate with antineoplastic agentsGENESNPAllelic variantpCR, n=21No pCR, n=96pDPYDrs17376848T/T13 (61.9%)83 (86.4%)0.007 C/T8 (38.1%)11 (11.4%) CDArs2072671A/A6 (28.5%)51 (53.1%)0.013 A/C15 (71.4%)36 (37.5%) C/C09 (9.3%) PPARDrs1883322T/T21 (100%)69 (71.8%)0.022 C/T022 (22.9%) C/C05 (5.2%) GSTM3rs7483A/A7 (33.3%)20 (20.8%)0.024 A/G13 (61.9%)43 (44.7%) G/G1 (4.7%)33 (34.3%) pCR= pathologic complete response
After logistic regression analysis, pCR predictive factors were the presence of grade-3 tumors OR=6.66 (95%CI=1.67-26.56), Ki67 ≥14% OR=15.45 (95%CI=1.71–138.86), premenopausal status OR=6.540 (95%CI=1.50–28.38) and A/A or A/G allele in rs7483 SNP (GSTM3 gene) OR=19.16 (95%CI=1.97–185.93).
Conclusions
Genetic variability encoded in the DMET-chip, could be helpful as a predictive factor of pCR in patients with Luminal HER2(-) LABC, but only in combination with other factors such as grade-3 tumors, elevated Ki67, and premenopausal status.
Citation Format: Ruvalcaba-Limon E, Rodriguez-Cuevas S, Hidalgo-Miranda A, Villa-Romero A, Bautista-Piña V, Rebollar-Vega R, Fernandez-Lopez JC, Morales-Vasquez F. Predictive factors of pathologic complete response to neoadjuvant chemotherapy in patients with Luminal HER2(-) local advanced breast cancer using the DMET microarray [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-18.
Collapse
Affiliation(s)
- E Ruvalcaba-Limon
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - S Rodriguez-Cuevas
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - A Hidalgo-Miranda
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - A Villa-Romero
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - V Bautista-Piña
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - R Rebollar-Vega
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - JC Fernandez-Lopez
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| | - F Morales-Vasquez
- Breast Diseases Institute and Breast Cancer Fundation (IEM-FUCAM), Coyoacan, Mexico City, Mexico; Cancer Genomics Laboratory, National Genomics Institution, Tlalpan, Mexico City, Mexico; Faculty of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
| |
Collapse
|
6
|
Fernandez-Lopez JC, Laffon A, Blanco FJ, Carmona L. Prevalence, risk factors, and impact of knee pain suggesting osteoarthritis in Spain. Clin Exp Rheumatol 2008; 26:324-332. [PMID: 18565256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVE To estimate the point prevalence of knee pain suggesting osteoarthritis (OA) in the adult Spanish population. Secondary objectives were to examine the distribution of associated factors, as well as to assess the impact of knee pain on quality of life and function in the general population. METHODS A population survey was conducted in year 2000 for which 2,192 subjects over 20 years of age were selected by stratified polystage cluster sampling from the censuses of 20 towns. Trained rheumatologists administered structured interviews that permitted them to rule out the presence of rheumatic symptoms, and which included validated instruments to measure function and quality of life. We used the definition of clinical symptomatic knee OA of the American College of Rheumatology. RESULTS The estimated prevalence of knee pain suggesting OA in the general adult population is 10.2% (95% confidence interval: 7.9-12.5). Elderly women with fewer studies and from the lower social class, as well as those subjects involved in physically demanding jobs are more frequently affected. Obesity is also an important determinant for knee pain suggesting OA. Knee pain is associated to a significant decrease in functional ability and quality of life, even after adjustment for age, sex, and comorbidity. CONCLUSION The prevalence of knee pain suggesting OA in the general Spanish population is higher than expected, mainly related to a high rate of knee pain in women over 55. The proportion of very old persons and of those obese are important factors to take into account when comparing the rate of knee OA between populations.
Collapse
Affiliation(s)
- J C Fernandez-Lopez
- Rheumatology Division, Complejo Hospitalario Universitario Juan Canalejo A. Coruña, Spain
| | | | | | | |
Collapse
|